Page 82 - Zai Lab News Today

Press release content from Business Wire. The AP news staff was not involved in its creation. Global Non-Small Cell Lung Cancer (NSCLC) Disease Insights and Market Forecasts Report 2020-2026 - ResearchAndMarkets.com January 6, 2021 GMT DUBLIN--(BUSINESS WIRE)--Jan 6, 2021-- “Non-small cell lung cancer (NSCLC) : Disease Insights and Market Forecasts to 2026” report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of NSCLC disease in the US, EU5 (Germany...

Author Bio Alex began writing for the Fool in early 2020 and follows companies in the healthcare sector. Formerly a researcher in the biotech industry, he leverages his science background in his work as a writer and entrepreneur. His interests include exploring his hometown of Boston, traveling in Latin America, and value investing. Follow @alexcarchidi Every healthcare facility is backed by an army of medical device companies. From critical hardware like car...

Zai Lab Announces Upcoming Presentation at 39th Annual J.P. Morgan Healthcare Conference

[December 28, 2020] Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in Chinas National Reimbursement Drug List SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA® has been included in the updated National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA). ZEJULA (niraparib) is an oral, once-da...

29.12.2020 - SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) - Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA has been included in the updated National Reimbursement ... Seite 1

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for ... Zai Lab LimitedDecember 28, 2020 GMT - Zai Lab to lead development and commercialization of CLN-081 in Greater China - Cullinan will receive $20 million upfront, up to $211 million in future milestones, and royalties - Zai Lab to join ongoing global trial for CLN-081 SHANGHAI and SAN FRANCISCO and CAMBRIDGE, M...

TikTok parent ByteDance hiring for AI drug discovery team ByteDance, TikTok’s Chinese parent company, is entering the health industry as it seeks to diversify a business dependent on advertising and livestreaming sales. The company, which prides itself on content algorithms, has started seeking talent in AI drug discovery across Mountain View, Shanghai and Beijing, its recruiting page shows. “We are looking for candidates to join our team and conduct cutting-edge research in drug discovery ...

With a new investment of USD 34 million, Avery Dennison is setting up a state-of-the-art manufacturing plant in Greater Noida, Uttar Pradesh (UP) as part of its strategy to achieve sustainable business growth and serve its key markets better. With this current investment, the overall investment numbers of India for Avery Dennison exceeds USD 136 million. The new facility would also enable the manufacturing of new innovative products, improve quality and serve its customers faster. Pankaj Bhard...

Re-envisioning the workforce: Skilling today to thrive tomorrow December 15, 2020 | Microsoft Stories Asia By Fiona Carney, Chief Marketing & Operations Officer, Microsoft Asia Pacific The COVID-19 pandemic has brought on one of the most challenging years in our lifetime – spurring a global economic crisis and severely impacting job markets. Our calculations show that global unemployment rates in 2020 may reach the staggering figure of a quarter of a billion people. At the same time...

Week Ahead In Pharma: FDA Decision, Review Of COVID-19 Vaccine, Data Readouts (Moderna, BCRX, ARVN...) THOUSAND OAKS (dpa-AFX) - The week that just passed by saw a couple of stocks belonging to the healthcare sector record triple-digit gains and nearly a dozen managing to log gains in excess of 50 percent, thanks to positive clinical trial readouts. Greenwich LifeSciences Inc. (GLSI), which closed out the week at $56, delivering over 890%, was the top gainer of the week, following promising fi...